5
1
7
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T41003 |
KG5
|
Raf; FLT; PDGFR; c-Kit | Angiogenesis; MAPK; Tyrosine Kinase/Adaptors |
KG5 是 PDGFRβ 和 B-Raf 的双重变构抑制剂,对 PDGFRβ 和 PDGFRα 的 Kd 分别为 520 nM 和 300 nM。 KG5 抑制 FLT3、KIT 和 c-Raf,具有抗癌和抗血管生成活性。 | |||
T35570 |
Chiauranib
CS2164,西奥罗尼 |
c-Fms; VEGFR; FLT; PDGFR; c-Kit; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Chiauranib 是一种针对肿瘤血管生成的多靶点抑制剂,具有强大的抗癌作用。 Chiauranib 有效抑制血管生成相关激酶(VEGFR1、VEGFR2、VEGFR3、PDGFRα 和 c-Kit)、有丝分裂相关激酶 Aurora B 和慢性炎症相关激酶 CSF1R,IC50 值范围为 1-9 nM。 | |||
T3476 |
JI-101
CGI-1842,JI 101 |
VEGFR; PDGFR; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
JI-101 (CGI-1842) 是一种有口服活性的多靶点激酶抑制剂,能够抑制VEGFR2,PDGFRβ和EphB4,具有抗癌作用。 | |||
T1792L |
Regorafenib monohydrate
|
Raf; VEGFR; c-RET; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Regorafenib monohydrate 是一种新型口服多激酶抑制剂,对VEGFR1/2/3、PDGFRβ、Kit、RET 和Raf-1的IC50分别为 13、4.2、46、22、7、1.5 和 2.5 nM。 | |||
T68286 |
CE-245677 mesylate
|
||
CE-245677 is a selective, orally active Tie2 kinase inhibitor identified by Pfizer previously in development for the treatment of certain cancers. CE-245,677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50 of 4.7 and 1 nM, resp., displays >100x selectivity against a number of other angiogenic receptor tyrosine kinases (e.g. KDR, PDGFR, FGFR) and gene family panels, and demonstrates good oral absorption in in vivo rat PK studies (F=80%). |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2734 |
Sennoside B
番泻苷 B,番泻苷B |
PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Sennoside B 是在番泻叶的叶子和豆荚中大量发现的蒽醌苷。它可通过与 PDGF-BB 及其受体结合并下调 PDGFR-β 信号传导途径来抑制 PDGF 刺激的细胞增殖。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00422 |
PDGF R beta/CD140b Protein, Human, Recombinant (His & Avi), Biotinylated
PDGFR-2,PDGF R β/CD140b,PDGFR1,CD... |
Human | HEK293 Cells |
PDGF R beta/CD140b Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 59 kDa and the accession number is P09619. | |||
TMPK-00421 |
PDGF R beta/CD140b Protein, Human, Recombinant (His & Avi)
PDGFR1,CD140B,PDGFR-2,PDGF R β/CD... |
Human | HEK293 Cells |
PDGF R beta/CD140b Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 59 kDa and the accession number is P09619. | |||
TMPK-01050 |
PDGF R beta/CD140b Protein, Canine, Recombinant (His)
JTK12,PDGF R β,PDGFR-β,PDGFR,PDGFR |
Canine | HEK293 Cells |
PDGF R beta/CD140b Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 57.25 kDa and the accession number is Q6QNF3. | |||
TMPK-00481 |
PDGF R beta/CD140b Protein, Cynomolgus, Recombinant (His)
PDGF R beta,PDGFRB,PDGFR... |
Cynomolgus | HEK293 Cells |
Platelet-derived growth factor receptor (PDGFR) signaling is involved in proliferation and survival in a wide array of cell types.PDGFR-β signalling, via TGF-β signalling, may be crucial for restoration of BBB integrity after cerebral ischemia and therefore represents a novel potential therapeutic target. | |||
TMPK-01413 |
H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)
H-2K,OVA,MHC,H2-K1 |
Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se... | |||
TMPK-01412 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)
SARS-CoV-2 epitope,MHC |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01416 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,SARS-CoV-2 epitope |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. |